The Journal of thoracic and cardiovascular surgery
-
J. Thorac. Cardiovasc. Surg. · Nov 2024
Impact of TAVR Utilization Ratio on Outcomes in Patients with Aortic Valve Disease.
Use of the Heart Team has been the standard of care for the treatment of aortic valve disease; however, its efficacy has not been evaluated. We sought to analyze its impact using the transcatheter aortic valve replacement (TAVR) use ratio (number of TAVR/total aortic valve replacement [AVR] volume) on TAVR, surgical aortic valve replacement (SAVR), and overall AVR outcomes. ⋯ Centers with balanced TAVR ratios had superior outcomes compared with centers with low or high ratios. These data support the use of a balanced Heart Team to optimize AVR outcomes.
-
J. Thorac. Cardiovasc. Surg. · Nov 2024
Living on the Edge: Role of Adjuvant Therapy After Resection of Primary Lung Cancer Within 2 Millimeters of a T-Stage Cutoff.
To evaluate the use of systemic therapy and overall survival in patients with resected non-small cell lung cancer whose pathologic tumor size was within 2 mm of a T-stage cutoff. ⋯ Rounding of tumor size for pathologic staging is common. Although seemingly trivial, rounding may downstage patients and is associated with decreased rates of adjuvant therapy use and potentially worse overall survival.
-
J. Thorac. Cardiovasc. Surg. · Nov 2024
Current outcomes of systemic-to-pulmonary artery shunt in patients with biventricular circulation.
This study investigated the outcomes after systemic-to-pulmonary artery shunt in patients with biventricular circulation. ⋯ In the current era, the systemic-to-pulmonary artery shunt is a safe and useful option for patients with biventricular circulation. In patients with risk factors for in-hospital major adverse shunt-related events, meticulous efforts should be directed toward preventing pulmonary overcirculation to further enhance outcomes.